CN106511616A - Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof - Google Patents
Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof Download PDFInfo
- Publication number
- CN106511616A CN106511616A CN201611076262.1A CN201611076262A CN106511616A CN 106511616 A CN106511616 A CN 106511616A CN 201611076262 A CN201611076262 A CN 201611076262A CN 106511616 A CN106511616 A CN 106511616A
- Authority
- CN
- China
- Prior art keywords
- cardiovascular
- parts
- pheretima
- vitamin
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 58
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 56
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 238000005516 engineering process Methods 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 241000218628 Ginkgo Species 0.000 claims abstract description 51
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 51
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 51
- 238000003756 stirring Methods 0.000 claims abstract description 34
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 229960004799 tryptophan Drugs 0.000 claims abstract description 10
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract description 6
- 235000019698 starch Nutrition 0.000 claims abstract description 6
- 239000008107 starch Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 3
- 241000237636 Pheretima Species 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 48
- 239000008187 granular material Substances 0.000 claims description 42
- 239000000047 product Substances 0.000 claims description 33
- 229930003231 vitamin Natural products 0.000 claims description 25
- 235000013343 vitamin Nutrition 0.000 claims description 25
- 239000011782 vitamin Substances 0.000 claims description 25
- 229940088594 vitamin Drugs 0.000 claims description 25
- 230000006806 disease prevention Effects 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 238000000855 fermentation Methods 0.000 claims description 15
- 230000004151 fermentation Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- -1 compound vitamin Chemical class 0.000 claims description 14
- 238000001291 vacuum drying Methods 0.000 claims description 13
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 244000061456 Solanum tuberosum Species 0.000 claims description 5
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000010902 straw Substances 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- 229930003537 Vitamin B3 Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 235000019160 vitamin B3 Nutrition 0.000 claims description 4
- 239000011708 vitamin B3 Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 241000243684 Lumbricus Species 0.000 abstract 4
- 241001092040 Crataegus Species 0.000 abstract 2
- 235000014493 Crataegus Nutrition 0.000 abstract 2
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 244000063299 Bacillus subtilis Species 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 206010059245 Angiopathy Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010057315 Daydreaming Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 241001310146 Ilex cornuta Species 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010039163 Right ventricular failure Diseases 0.000 description 2
- 206010040026 Sensory disturbance Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229940071462 oralone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000026473 slurred speech Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and a preparation technology thereof. The preparation steps are as follows: weighting the raw materials in parts by weight, including lumbricus, ginkgo nuts, cortex cinnamomi, hawthorns, wolfberry, multivitamin and L-tryptophan; adopting bifidobacterium strain, saccharomyces cerevisiae strain and bacillus natto for fermenting the lumbricus, thereby obtaining the fermented lumbricus; adopting the saccharomyces cerevisiae for fermenting the ginkgo nuts, thereby obtaining the fermented ginkgo nuts; drying and smashing the cortex cinnamomi, the hawthorns and the wolfberry, adding an alcohol solution, stirring, soaking, ultrasonically treating, filtering and concentrating, thereby obtaining a concentrated solution; mixing the fermented lumbricus, the fermented ginkgo nuts and the concentrated solution, and then stirring, adding the multivitamin and the L-tryptophan and continuing to stir, adding starch and stirring, thereby obtaining the compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases. The compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases, prepared according to the preparation technology provided by the invention, is fit for the physical characteristics of the middle-aged people, the preventing efficiency reaches up to above 99% and the auxiliary treating effect is increased to above 91%.
Description
Technical field
The present invention relates to a kind of disease prevention and auxiliary treatment compositionss preparation technology, specifically a kind of cardiovascular and cerebrovascular vessel disease
Disease prevention and auxiliary treatment compositionss and its preparation technology.
Background technology
Cardiovascular and cerebrovascular disease is the general designation of cardiovascular and cerebrovascular disease, is referred to as hyperlipemia, blood are sticky, dynamic
Pulse atherosclerosis, hypertension etc. caused by the ischemic that occurs of heart, brain and body tissue or hemorrhage.
The common sympton of cardiovascular disease has：It is cardiopalmus, shortness of breath, orthopnea, nocturnal paroxysmal dyspnea, retrosternal
Repressive or girdle pain, discomfort uncomfortable in chest, edema, cyanosis, faint, spitting of blood of coughing, weakness, belch, upper abdominal pain, nausea, vomit
Tell；Left back backache, left hand brachialgia etc..Cerebrovascular disease can have hemiplegia, hemidysesthesia, hemianopsia, aphasia；Or intercrossing paralysis
Paralysis, contralateral sensory disturbance, ophthalmoplegia externa, nystagmuies, dysphagia, ataxia, dizziness etc.；Or limb adynamia, fiber crops
Wood, face, upper and lower extremities sensory disturbance；Unilateral limb motion is dumb；Aphasis, it is not agile to speak；Hypomnesis；See thing
Body is unclear suddenly；Or Rotation of eyeball is dumb；Urinary incontinence；Balanced capacity is lacked of proper care, astasia；Disturbance of consciousness；Headache or
Person's nausea and vomiting；Dizziness, tinnitus etc..
Cardiovascular and cerebrovascular disease is that one kind is serious threatens the mankind, the commonly encountered diseases of particularly more than 50 years old middle-aged and elderly people health, tool
The characteristics of having high prevalence, high disability rate and high mortality, even if application treatment meanss most advanced, perfect at present, can still have
More than 50% cerebrovas-cularaccident survivor life can not be taken care of oneself completely, and the number that cardiovascular and cerebrovascular disease is died from the whole world every year is high
Up to 15,000,000 people, the various causes of the death are occupied the first.Therefore, at present, the prevention and treatment of cardiovascular and cerebrovascular disease are very crucial；People is old 50 years old
After, body constitution can occur some obvious changes, and physiological function just turns to decline by containing, the regeneration capacity of life cells, immunocompetence,
Endocrine function etc. declines, and the function of the internal organs such as the heart, lung, brain, kidney is also unconsciously being faded, the absorption of the intestines and stomach
Function has also declined, it may be said that people in middle age has just stepped into eventful period.Cardiovascular and cerebrovascular disease can attack middle age, but
Symptom is but usually easily ignored, or is blanked because being busy with one's work, thus is not easily achieved early discovery and treatment.
The related health product of person in middle and old age's cardiovascular and cerebrovascular disease for occurring in the market, typically by simple Chinese medicine into
Divide what is be mixed；, easily there is side effect in absorption difference, causes certain burden to the intestines and stomach of person in middle and old age, is not suitable for long-term taking,
And slowly effect, change the present situation in the urgent need to a kind of new technology.
The content of the invention
It is an object of the present invention to provide a kind of cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss and its preparation technology, made
Standby cardiovascular and cerebrovascular disease prevention and auxiliary treatment composition effect significantly, easily absorb, instant effect, are adapted to long-term taking.
The present invention for the solution technical scheme that adopts of above-mentioned technical problem is：
Cardiovascular and cerebrovascular disease prevents the preparation technology with auxiliary treatment compositionss, comprises the following steps：
Step one, following raw material is taken respectively according to parts by weight：Pheretima 70-80 parts, ginkgo nut 13-20 parts, Cortex Cinnamomi 5-10 parts, mountain
0.05 part of short, bristly hair or beard 10-20 parts, Fructus Lycii 30-40 parts, compound vitamin 0.05-0.07 parts and L-Tryptophan, it is standby；
The preparation of step 2, Pheretima fermented product：
（1）, taken Pheretima is removed impurity, washing is clean, after 20-30 DEG C of vacuum drying, smashes into particle diameter for 2.5-3.2mm
Granule, obtain Pheretima granule, it is standby；The Semen Maydis powder of 0.8-1.9 times of Pheretima granular mass, 0.5-1.2 times of length are taken respectively
For 1-5mm corn straw and 3-5 times of water, mixing, after stirring, it is placed in 121 DEG C of high pressure steam sterilizations 30 minutes, cools down
To room temperature, mixture after being sterilized is standby；
（2）, Pheretima granule is added to after sterilizing in mixture, stir, obtain treating fermenting mixture；Treating fermentation mixing
Bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt bacterium after the amplification culture of its quality 1%-3% is respectively connected in thing
Kind, then in 28-30 DEG C of Anaerobic culturel 5-8 days, mixture after being fermented；Mixture after fermentation is carried out into 20-30 DEG C of vacuum
After drying, ultra micro smashing is carried out, that is, obtain Pheretima fermented product；
The preparation of step 3, ginkgo nut fermented product：
（1）, by ginkgo nut smash to particle diameter for 4-5mm granule；Its quality is added in Semen Ginkgo fruit granule of the particle diameter for 4-5mm
5-10 times of volumetric concentration is 80% ethanol water, soaks 6-8h, and taking-up is drained, and smashes into particle diameter again for 1.2-1.5mm
Semen Ginkgo fruit granule, it is standby；
（2）, particle diameter for 1.2-1.5mm Semen Ginkgo fruit granule in, add its quality 0.8-1.2 times dehydrated potato powder and 0.5 times
Water, after mix homogeneously, access the saccharomyces cerevisiae strain of its quality 2% in the resulting mixture, be placed in 28-30 DEG C of Anaerobic culturel
3-5 days, tunning is obtained, tunning is carried out, after 20-30 DEG C of vacuum drying, carrying out ultra micro smashing, that is, obtaining ginkgo nut
Fermented product；
Step 4, by Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii, dries pulverizing crosses 20-30 mesh sieves；Add its weight 5-10 in gained powder
Times by volume ratio be 2:The ethanol water of 1 second alcohol and water composition, after stirring, soaks 24-48 hours, then carries out
Ultrasound, filters, obtains filtrate, standby；Gained filtrate carries out 5-6 times using condenser and concentrates, and reclaims ethanol, is concentrated
Liquid, it is standby；
Step 5, by the mixing of Pheretima fermented product obtained by above-mentioned steps, ginkgo nut fermented product and concentrated solution after, stir 10-15min,
Add compound vitamin and L-Tryptophan to continue stirring 10-20min, be eventually adding the starch of 2-5 times of mixture quality of gained, stir
30min is mixed, that is, prepares cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss.
Supersonic frequency described in step 4 is 500Hz-600Hz, and the time is 20-25min.
Cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss prepared by the preparation technology, can be prepared as pill, powder
Agent, tablet, granule or capsule.
Prepared by the preparation technology, cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss can be applicable to
Medicine.
Cardiovascular and cerebrovascular disease prevention and application of the auxiliary treatment compositionss in health food prepared by the preparation technology.
Cardiovascular and cerebrovascular disease prevention and application of the auxiliary treatment compositionss in functional drinkss prepared by the preparation technology.
Beneficial effect is：
1st, the preparation technology of cardiovascular and cerebrovascular disease prevention of the present invention and auxiliary treatment compositionss, the technique is according to pharmaceutical compositions feature
And design, each reasonable raw material proportioning；Under the process of technique, the mutual synergy of each medicine more preferably, is easily inhaled by person in middle and old age's human body
Receive, instant effect, prevention effective percentage reaches more than 99%, and adjuvant treatment effect is improved to more than 91%；The technique is to Pheretima and Semen Ginkgo
Fruit is fermented, and wherein Pheretima has selected bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt as fermentation
Bacterium, coordinates related fermentation technology, prepared Pheretima fermented product is more beneficial for being combined with the ginkgo nut of fermentation and is reached control
The state of an illness of person in middle and old age's cardiovascular and cerebrovascular disease, the purpose of effective auxiliary treatment；Pheretima fermentation technology in the technique be more beneficial for
After being combined using the ginkgo nut that the application technique is fermented, the extraction concentrated solution work with the material such as Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii institute jointly
With the material combination for making drug effect and absorbance significantly larger than simple.
2nd, the cardiovascular and cerebrovascular disease prevention prepared by the present invention and auxiliary treatment compositionss, the body for meeting person in middle and old age are special
Point, easily absorbs, instant effect；The materials such as Pheretima, ginkgo nut, Cortex Cinnamomi are Chinese medicine, it is generally the case that after only simply being extracted
The medicine of combination, is also easy to produce side effect, and assimilation effect is poor, long-term taking, easily the body of person in middle and old age is produced it is various can not be pre-
The harmful effect seen；The preparation technology of the present invention, solves in prior art, is mutually tied by simple several raw extracts
Prepared compositionss after conjunction, long-term taking are also easy to produce the defect of drug side effect；And solve as the body of person in middle and old age is special
The problems such as point causes medicine to be difficult absorption, adjuvant treatment effect difference more；Verified by clinical trial, by present invention process system
Standby cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss, Jing informal dresses can use for a long time, have no side effect, safety, good absorbing, auxiliary
Treat and prevent cardiovascular and cerebrovascular disease effect is significant.
Specific embodiment
Cardiovascular and cerebrovascular disease of the present invention is prevented with reference to embodiment and auxiliary treatment compositionss preparation technology make into
The explanation of one step：
Embodiment 1
Cardiovascular and cerebrovascular disease prevents the preparation technology with auxiliary treatment compositionss, comprises the following steps：
Step one, take following raw material according to parts by weight respectively, 80 parts of Pheretima, 20 parts of ginkgo nut, 10 parts of Cortex Cinnamomi, 20 parts of Fructus Crataegi,
40 parts of Fructus Lycii, 0.07 part and 0.05 part L-Tryptophan of compound vitamin, it is standby；
The preparation of step 2, Pheretima fermented product：
（1）, taken Pheretima is removed impurity, washing is clean, after 20 DEG C of vacuum drying, smashes into the granule that particle diameter is 2.5mm,
Pheretima granule is obtained, it is standby；Take the Semen Maydis powder of 0.8 times of Pheretima granular mass, 0.5 times of Pheretima granular mass respectively to be crushed to
The water of 3 times of 1mm corn straw and Pheretima granular mass, mixing, after stirring, is placed in 30 points of 121 DEG C of high pressure steam sterilizations
Clock, is cooled to room temperature, mixture after being sterilized, standby；
（2）, Pheretima granule is added to after sterilizing in mixture, stir, obtain treating fermenting mixture；Treating fermentation mixing
Bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt strain after the amplification culture of its quality 1% is respectively connected in thing,
Then in 28 DEG C of Anaerobic culturels 5 days, mixture after being fermented；Mixture after fermentation is carried out, after 20 DEG C of vacuum drying, carrying out
Ultra micro is smashed, that is, obtain Pheretima fermented product；
The preparation of step 3, ginkgo nut fermented product：
（1）, by ginkgo nut smash to particle diameter for 4mm granule, obtain Semen Ginkgo fruit granule；Its quality is added in Semen Ginkgo fruit granule
5 times of volumetric concentration is that 80% ethanol water soaks 6h, and taking-up is drained, and smashes into the ginkgo nut that particle diameter is 1.2mm again
Grain, it is standby；
（2）, in Semen Ginkgo fruit granule of the particle diameter for 1.2mm, add the dehydrated potato powder of 0.8 times of its quality and 0.5 times of water, mix
After closing uniformly, the saccharomyces cerevisiae strain of its quality 2% is accessed in the resulting mixture, 28 DEG C of Anaerobic culturels is placed in 5 days, is sent out
Ferment product, tunning is carried out, after 20 DEG C of vacuum drying, carrying out ultra micro smashing, that is, obtaining ginkgo nut fermented product；
Step 4, by Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii, dries pulverizing crosses 20 mesh sieves；Add in gained powder 5 times of its weight by
Volume ratio is 2:The ethanol water of 1 second alcohol and water composition, after stirring, soaks 24 hours, then carries out ultrasound, mistake
Filter, obtains filtrate, standby；Gained filtrate carries out 5 times of concentrations using condenser, and reclaims ethanol, obtains concentrated solution, standby；
Step 5, by Pheretima fermented product, ginkgo nut fermented product and concentrated solution mix after, stir 10min, add compound vitamin and
L-Tryptophan continues stirring 10min, is eventually adding the starch of 2 times of mixture quality of gained, stirs 30min, that is, the heart and brain for preparing
Angiopathy prevents and auxiliary treatment compositionss.
The compound vitamin, is made up of the vitamin of following parts by weight, 0.01 part of vitamin B3, vitamin C 0.1
Part, 0.013 part of Vitamin E, 0.001 part of vitamin B1,0.001 part of vitamin B6,0.000004 part of Vitamin B12 and leaf
0.0003 part of acid.
Supersonic frequency described in step 4 is 500Hz, and the time is 20min.
Cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss prepared by the preparation technology, can be prepared as pill, powder
Agent, tablet, granule or capsule.
Embodiment 2
Cardiovascular and cerebrovascular disease prevents the preparation technology with auxiliary treatment compositionss, comprises the following steps：
Step one, take following raw material according to parts by weight respectively, 70 parts of Pheretima, 13 parts of ginkgo nut, 5 parts of Cortex Cinnamomi, 10 parts of Fructus Crataegi, Chinese holly
30 parts of Qi, 0.05 part and 0.05 part L-Tryptophan of compound vitamin, it is standby；
The preparation of step 2, Pheretima fermented product：
（1）, taken Pheretima is removed impurity, washing is clean, after 30 DEG C of vacuum drying, smashes into the granule that particle diameter is 3.2mm,
Pheretima granule is obtained, it is standby；The Semen Maydis powder of 0.8 times of Pheretima granular mass, 1.2 times of Pheretima granular mass are taken respectively is crushed to length
The water for 5 times of 5mm corn straw and Pheretima granular mass is spent, is mixed, after stirring, is placed in 121 DEG C of high pressure steam sterilizations 30
Minute, room temperature is cooled to, mixture after being sterilized is standby；
（2）, Pheretima granule is added to after sterilizing in mixture, stir, obtain treating fermenting mixture；Treating fermentation mixing
Bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt strain after the amplification culture of its quality 3% is respectively connected in thing,
Then in 30 DEG C of Anaerobic culturels 8 days, mixture after being fermented；Mixture after fermentation is carried out, after 30 DEG C of vacuum drying, carrying out
Ultra micro is smashed, that is, obtain Pheretima fermented product；
The preparation of step 3, ginkgo nut fermented product：
（1）, by ginkgo nut smash to particle diameter for 5mm granule, obtain Semen Ginkgo fruit granule；Its quality is added in Semen Ginkgo fruit granule
10 times of volumetric concentration is that 80% ethanol water soaks 6-8h, and taking-up is drained, and smashes into the Semen Ginkgo that particle diameter is 1.5mm again
Fruit granule, it is standby；
（2）, be the Semen Ginkgo fruit granule of 1.5mm in particle diameter, add the dehydrated potato powder of 1.2 times of its quality and 0.5 times of water, mixing is equal
The saccharomyces cerevisiae strain of its quality 2% after even, is accessed in the resulting mixture, 30 DEG C of Anaerobic culturels is placed in 5 days, is obtained fermentation and is produced
Thing, tunning is carried out, after 30 DEG C of vacuum drying, carrying out ultra micro smashing, that is, obtaining ginkgo nut fermented product；
Step 4, by Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii, dries pulverizing crosses 30 mesh sieves；Add in gained powder 10 times of its weight by
Volume ratio is 2:The ethanol water of 1 second alcohol and water composition, after stirring, soaks 48 hours, then carries out ultrasound, mistake
Filter, obtains filtrate, standby；Gained filtrate carries out 6 times of concentrations using condenser, and reclaims ethanol, obtains concentrated solution, standby；
Step 5, by Pheretima fermented product, ginkgo nut fermented product and concentrated solution mix after, stir 15min, add compound vitamin and
L-Tryptophan continues stirring 20min, is eventually adding the starch of 5 times of mixture quality of gained, stirs 30min, that is, the heart and brain for preparing
Angiopathy prevents and auxiliary treatment compositionss.
The compound vitamin, is made up of the vitamin of following parts by weight, and 0.05 part of vitamin B3, vitamin C-
0.3 part, 0.017 part of Vitamin E, 0.003 part of vitamin B1,0.003 part of vitamin B6,0.000008 part of Vitamin B12 and
0.0007 part of Folic Acid.
Supersonic frequency described in step 4 is 600Hz, and the time is 25min.
Cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss prepared by the preparation technology, can be prepared as pill, powder
Agent, tablet, granule or capsule.
Embodiment 3
Cardiovascular and cerebrovascular disease prevents the preparation technology with auxiliary treatment compositionss, comprises the following steps：
Step one, take following raw material according to parts by weight respectively, 76 parts of Pheretima, 14 parts of ginkgo nut, 8 parts of Cortex Cinnamomi, 15 parts of Fructus Crataegi, Chinese holly
35 parts of Qi, 0.06 part and 0.05 part L-Tryptophan of compound vitamin, it is standby；
The preparation of step 2, Pheretima fermented product：
（1）, taken Pheretima is removed impurity, washing is clean, after 25 DEG C of vacuum drying, smashes into the granule that particle diameter is 2.8mm,
Pheretima granule is obtained, it is standby；The Semen Maydis powder of 1.2 times of Pheretima granular mass, 1.2 times of Pheretima granular mass are taken respectively is crushed to length
The water for 4 times of 4mm corn straw and Pheretima granular mass is spent, is mixed, after stirring, is placed in 121 DEG C of high pressure steam sterilizations 30
Minute, room temperature is cooled to, mixture after being sterilized is standby；
（2）, Pheretima granule is added to after sterilizing in mixture, stir, obtain treating fermenting mixture；Treating fermentation mixing
Bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt strain after the amplification culture of its quality 2% is respectively connected in thing,
Then in 29 DEG C of Anaerobic culturels 6 days, mixture after being fermented；Mixture after fermentation is carried out, after 25 DEG C of vacuum drying, carrying out
Ultra micro is smashed, that is, obtain Pheretima fermented product；
The preparation of step 3, ginkgo nut fermented product：
（1）, by ginkgo nut smash to particle diameter for 4.5mm granule, obtain Semen Ginkgo fruit granule；Its matter is added in Semen Ginkgo fruit granule
The volumetric concentration of 8 times of amount is that 80% ethanol water soaks 7h, and taking-up is drained, and smashes into the ginkgo nut that particle diameter is 1.3mm again
Granule, it is standby；
（2）, particle diameter for 1.2-1.5mm Semen Ginkgo fruit granule in, add the dehydrated potato powder of 1.1 times of its quality and 0.5 times of water,
The saccharomyces cerevisiae strain of its quality 2% after mix homogeneously, is accessed in the resulting mixture, 29 DEG C of Anaerobic culturels is placed in 4 days, is obtained
Tunning, tunning is carried out, after 25 DEG C of vacuum drying, carrying out ultra micro smashing, that is, obtaining ginkgo nut fermented product；
Step 4, by Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii, dries pulverizing crosses 25 mesh sieves；Add in gained powder 8 times of its weight by
Volume ratio is 2:The ethanol water of 1 second alcohol and water composition, after stirring, soaks 30 hours, then carries out ultrasound, mistake
Filter, obtains filtrate, standby；Gained filtrate carries out 5.5 times of concentrations using condenser, and reclaims ethanol, obtains concentrated solution, standby；
Step 5, by Pheretima fermented product, ginkgo nut fermented product and concentrated solution mix after, stir 12min, add compound vitamin and
L-Tryptophan continues stirring 15min, is eventually adding the starch of 4 times of mixture quality of gained, stirs 30min, that is, the heart and brain for preparing
Angiopathy prevents and auxiliary treatment compositionss.
The compound vitamin, is made up of the vitamin of following parts by weight, 0.03 part of vitamin B3, vitamin C 0.2
Part, 0.015 part of Vitamin E, 0.002 part of vitamin B1,0.002 part of vitamin B6,0.000006 part of Vitamin B12 and leaf
0.0005 part of acid.
Supersonic frequency described in step 4 is 550Hz, and the time is 22min.
Cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss prepared by the preparation technology, can be prepared as pill, powder
Agent, tablet, granule or capsule.
Relevant clinical prophylactic tria data
1st, subjects：From the random choose age in healthy population of the Jing Health Certificates without cardiovascular and cerebrovascular disease 45-80 year
Middle-aged and elderly people 300, wherein male 150, women 150；
2nd, test method：The powder or tablet for taking cardiovascular and cerebrovascular disease prevention of the present invention and auxiliary treatment compositionss is used to prevent
Cardiovascular and cerebrovascular disease and conditioning body and the mental status；The instructions of taking of powder is, 2 times a day, once oral one bag, per bag
1g；The instructions of taking of tablet is, 2 times a day, once oral 2.
4th, test effect：The present invention is taken after 1 month, 295 experimenters start to feel that the mental status is good, sleep, eat
Be intended to it is good, without any cardiovascular and cerebrovascular disease symptom；After taking 6 months, wherein 200 experimenters remove the shape occurred after taking 1 month
Outside state, have rosy cheeks, it is dynamic；After taking 1 year, 300 experimenters are checked UP again, blood pressure stabilization, without heart and brain blood
Pipe disease occurs.
Test result indicate that, cardiovascular and cerebrovascular disease prevention of the present invention and auxiliary treatment compositionss can effectively prevent cardiovascular and cerebrovascular vessel
Disease, effective prevention rate reach 100%, and the appearance that has no side effect.
Relevant clinical auxiliary treatment test data
1st, subjects：It is divided into two groups, one group is clinical trial group, and the group selects the cardiovascular and cerebrovascular vessel disease that Jing three-levels are made a definite diagnosis to go to the hospital
Patient, 200, its cardiovascular disease 120, cerebrovascular disease 80.Another group be matched group, the group select Jing three-levels with
Go to the hospital the Patients with Cardiovascular/Cerebrovascular Diseases made a definite diagnosis, 200, its cardiovascular disease 120, cerebrovascular disease 80.
2nd, test method：
Test group：Take the powder or tablet auxiliary prevention heart and brain of cardiovascular and cerebrovascular disease prevention of the present invention and auxiliary treatment compositionss
Angiopathy；The instructions of taking of powder is, 2 times a day, once oral one bag, every bag of 1g；The instructions of taking of tablet is, one day 2
It is secondary, once oral 2.Simultaneously according to doctor is prescribed or other treatment mode continual cure；
Matched group：According to doctor is prescribed or other treatment mode continual cure；
3rd, treat evaluation criterion：
A, cardiovascular disease evaluation criterion：
Cure：General malaise symptoms (cough, cardiopalmus, arrhythmia, spitting of blood, palpitation and short breath, fatigue, it is tired after cardiopalmus, cyanosis,
Distension of jugular vein) disappear, right heart failure, hepatomegaly disappear on inspection；
It is effective：General malaise symptoms (cough, cardiopalmus, arrhythmia, spitting of blood, palpitation and short breath, fatigue, it is tired after cardiopalmus, cyanosis,
Distension of jugular vein) mitigate or disappear, right heart failure takes a turn for the better on inspection, hepatomegaly is substantially reduced；
Effectively：Meet healing or effective standard.
It is invalid：The state of an illness is unchanged on inspection.
B, cerebrovascular disease evaluation criterion
Cure：General malaise symptoms（Headache, dizziness, tinnitus, twitching of the eyelid, blurring of vision are uncomfortable in chest, feel suffocated, and fidgety, irritability is forgetful,
It is worried, asthenia is powerless, absentminded.At the beginning of morbidity, One's head is splitting, slurred speech, visually impaired, vomiting etc.）Disappear, half body paralysed disease
Shape takes a turn for the better, and debates thing knowledge people normal；
It is effective：General malaise symptoms（Headache, dizziness, tinnitus, twitching of the eyelid, blurring of vision are uncomfortable in chest, feel suffocated, and fidgety, irritability is forgetful,
It is worried, asthenia is powerless, absentminded.At the beginning of morbidity, One's head is splitting, slurred speech, visually impaired, vomiting）Mitigate, half body paralysis symptom
Mitigate, debate thing and know the enhancing of people's ability；
Effectively：Meet healing or effective standard.
It is invalid：The state of an illness is unchanged on inspection.
4th, therapeutic effect：
Test group：200 patients for being treated, wherein curing cardiovascular disease 40, cure cerebrovascular disease 30；Painstaking effort
Pipe disease is effective 50, and cerebrovascular disease is effective 20；Total effective rate is up to 70%.
Matched group：200 patients for being treated, wherein curing cardiovascular disease 70, cure cerebrovascular disease 53；
Cardiovascular disease is effective 55, and cerebrovascular disease is effective 5；Total effective rate is up to 91.5%.
As a result show that the treated effect of person in middle and old age's cardiovascular and cerebrovascular disease can be carried by Chinese medicine formula reasonable recipe of the present invention
High 21.5% effective percentage that can significantly improve treatment person in middle and old age cardiovascular and cerebrovascular disease prevention, auxiliary treatment person in middle and old age's cardiovascular and cerebrovascular vessel disease
Sick effect is significant.
Claims (7)
1. cardiovascular and cerebrovascular disease prevents the preparation technology with auxiliary treatment compositionss, it is characterised in that：Comprise the following steps：
Step one, following raw material is taken respectively according to parts by weight：Pheretima 70-80 parts, ginkgo nut 13-20 parts, Cortex Cinnamomi 5-10 parts, mountain
0.05 part of short, bristly hair or beard 10-20 parts, Fructus Lycii 30-40 parts, compound vitamin 0.05-0.07 parts and L-Tryptophan, it is standby；
The preparation of step 2, Pheretima fermented product：
（1）, taken Pheretima is removed impurity, washing is clean, after 20-30 DEG C of vacuum drying, smashes into particle diameter for 2.5-3.2mm
Granule, obtain Pheretima granule, it is standby；The Semen Maydis powder of 0.8-1.9 times of Pheretima granular mass, 0.5-1.2 times of length are taken respectively
For 1-5mm corn straw and 3-5 times of water, mixing, after stirring, it is placed in 121 DEG C of high pressure steam sterilizations 30 minutes, cools down
To room temperature, mixture after being sterilized is standby；
（2）, Pheretima granule is added to after sterilizing in mixture, stir, obtain treating fermenting mixture；Treating fermentation mixing
Bifidobacterium species, saccharomyces cerevisiae strain and Bafillus natt bacterium after the amplification culture of its quality 1%-3% is respectively connected in thing
Kind, then in 28-30 DEG C of Anaerobic culturel 5-8 days, mixture after being fermented；Mixture after fermentation is carried out into 20-30 DEG C of vacuum
After drying, ultra micro smashing is carried out, that is, obtain Pheretima fermented product；
The preparation of step 3, ginkgo nut fermented product：
（1）, by ginkgo nut smash to particle diameter for 4-5mm granule；Its quality is added in Semen Ginkgo fruit granule of the particle diameter for 4-5mm
5-10 times of volumetric concentration is 80% ethanol water, soaks 6-8h, and taking-up is drained, and smashes into particle diameter again for 1.2-1.5mm
Semen Ginkgo fruit granule, it is standby；
（2）, particle diameter for 1.2-1.5mm Semen Ginkgo fruit granule in, add its quality 0.8-1.2 times dehydrated potato powder and 0.5 times
Water, after mix homogeneously, access the saccharomyces cerevisiae strain of its quality 2% in the resulting mixture, be placed in 28-30 DEG C of Anaerobic culturel
3-5 days, tunning is obtained, tunning is carried out, after 20-30 DEG C of vacuum drying, carrying out ultra micro smashing, that is, obtaining ginkgo nut
Fermented product；
Step 4, by Cortex Cinnamomi, Fructus Crataegi and Fructus Lycii, dries pulverizing crosses 20-30 mesh sieves；Add its weight 5-10 in gained powder
Times by volume ratio be 2:The ethanol water of 1 second alcohol and water composition, after stirring, soaks 24-48 hours, then carries out
Ultrasound, filters, obtains filtrate, standby；Gained filtrate carries out 5-6 times using condenser and concentrates, and reclaims ethanol, is concentrated
Liquid, it is standby；
Step 5, by the mixing of Pheretima fermented product obtained by above-mentioned steps, ginkgo nut fermented product and concentrated solution after, stir 10-15min,
Add compound vitamin and L-Tryptophan to continue stirring 10-20min, be eventually adding the starch of 2-5 times of mixture quality of gained, stir
30min is mixed, that is, prepares cardiovascular and cerebrovascular disease prevention and auxiliary treatment compositionss.
2. cardiovascular and cerebrovascular disease as claimed in claim 1 prevents the preparation technology with auxiliary treatment compositionss, it is characterised in that：Institute
Compound vitamin is stated, is made up of the vitamin of following parts by weight, vitamin B3 0.01-0.05 parts, vitamin C 0.1-0.3
Part, Vitamin E 0.013-0.017 part, vitamin B1 0.001-0.003 parts, vitamin B6 0.001-0.003 parts, vitamin
B12 0.000004-0.000008 parts and Folic Acid 0.0003-0.0007 part.
3. cardiovascular and cerebrovascular disease as claimed in claim 1 prevents the preparation technology with auxiliary treatment compositionss, it is characterised in that：Step
Supersonic frequency described in rapid four is 500-600Hz, and the time is 20-25min.
4. cardiovascular and cerebrovascular disease prevention and auxiliary treatment prepared by the preparation technology as described in one of claim 1-3 is combined
Thing, it is characterised in that：Pill, powder, tablet, granule or capsule can be prepared as.
5. cardiovascular and cerebrovascular disease prevention and auxiliary treatment prepared by the preparation technology as described in one of claim 1-3 is combined
Application of the thing in medicine.
6. cardiovascular and cerebrovascular disease prevention and auxiliary treatment prepared by the preparation technology as described in one of claim 1-3 is combined
Application of the thing in health food.
7. cardiovascular and cerebrovascular disease prevention and auxiliary treatment prepared by the preparation technology as described in one of claim 1-3 is combined
Application of the thing in functional drinkss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611076262.1A CN106511616A (en) | 2016-11-30 | 2016-11-30 | Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611076262.1A CN106511616A (en) | 2016-11-30 | 2016-11-30 | Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511616A true CN106511616A (en) | 2017-03-22 |
Family
ID=58355176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611076262.1A Pending CN106511616A (en) | 2016-11-30 | 2016-11-30 | Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511616A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208654A (en) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | Healthcare prescription mainly containing earthworm protein extract |
-
2016
- 2016-11-30 CN CN201611076262.1A patent/CN106511616A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208654A (en) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | Healthcare prescription mainly containing earthworm protein extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102524781A (en) | Edible composition with alcoholism alleviation function and preparation method thereof | |
| US20220087926A1 (en) | Compound composition with anti-oxidation and anti-aging effects and preparation method and application thereof | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN104940645A (en) | Dendrobium officinale traditional Chinese medicine composition with functions of maintaining beauty and keeping young and preparation of dendrobium officinale traditional Chinese medicine composition | |
| CN110710678A (en) | Marine polypeptide donkey-hide gelatin paste capable of nourishing liver and kidney, nourishing blood and soothing nerves and preparation method thereof | |
| CN106418143A (en) | Composition for improving sleep and vision and application thereof | |
| CN107334870A (en) | A kind of composition of hypotensive and preparation method thereof | |
| CN101828740B (en) | Rhodiola rosea chrysanthemum root beverage with beautifying function | |
| CN105796981A (en) | Traditional Chinese medicine oral liquid for improving sub-health state and preparation method of traditional Chinese medicine oral liquid | |
| CN105709020A (en) | Foot bath powder with folium artemisiae argyi decoction dregs and preparation method thereof | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN103301341A (en) | Traditional Chinese medicine composition of treating ischemic cerebral apoplexy | |
| CN106511616A (en) | Compound for preventing and assisting in treating cardiovascular and cerebrovascular diseases and preparation technology thereof | |
| KR101293732B1 (en) | Method manufacture of liquor help slumber | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN103202964B (en) | Brain-improving and mind-calming medicinal liquor | |
| CN101884758B (en) | Food therapy preparation for preventing and treating cerebrovascular diseases based on theories of preventive treatment of disease and medicine food homology | |
| CN104623503A (en) | Traditional Chinese medicine preparation for treating hyperthyreosis and preparation process thereof | |
| CN109363182A (en) | A kind of food and medicament dual-purpose composition of postpartum enriching yin qi-restoratives and preparation method thereof | |
| CN106723024A (en) | The preparation method of person in middle and old age's cardiovascular and cerebrovascular disease health products | |
| CN103961578A (en) | Traditional Chinese medicine medicinal liquor for treating neurasthenia | |
| CN103585431B (en) | Traditional Chinese medicine composition for curing type I diabetes mellitus | |
| CN105561192A (en) | Cordyceps sinensis and fructus hippophae healthy medicinal liquor | |
| CN105999003A (en) | Folium artemisiae argyi healthcare liquor for preventing and treating dysmenorrhea and preparation method thereof | |
| CN106107258A (en) | A kind of Herba Dendrobii heat clearing away beautifying drink and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |